• Explore /
  • Poster
  • / Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Final analysis—Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial.

Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Final analysis—Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial.

Abstract Poster

Authors

null

Satoshi Yuki

Department of Gastroenterology, Hokkaido Universit

Satoshi Yuki , Yoshito Komatsu , Hiraku Fukushima , Takahide Sasaki , Toraji Amano , Takuto Miyagishima , Kazuteru Hatanaka , Michio Nakamura , Miki Tateyama , Yuh Sakata

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon and Rectum

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00569790

Citation

J Clin Oncol 31, 2013 (suppl 4; abstr460)

DOI

10.1200/jco.2013.31.4_suppl.460

Abstract #

460

Poster Bd #

C16

Abstract Disclosures

Similar Posters

First Author: Satoshi Yuki

First Author: Hideaki Bando

First Author: Scott Kopetz

First Author: Akihito Tsuji